VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Replimune Group
REPL
$466M
| $137K | 0.07% |
5,019
-2,134
| -30% | -$58K |
|
|
MORF
377
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $136K | 0.07% |
5,099
+31
| +0.6% | +$829 |
|
378
Ventyx Biosciences
VTYX
$184M
| $135K | 0.07% |
4,125
-3,898
| -49% | -$128K |
|
379
uniQure
QURE
$967M
| $135K | 0.07% |
5,955
-1,847
| -24% | -$41.9K |
|
|
ISEE
380
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $135K | 0.07% |
6,287
-4,788
| -43% | -$103K |
|
|
KRTX
381
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $135K | 0.07% |
685
-365
| -35% | -$71.7K |
|
382
Keros Therapeutics
KROS
$630M
| $134K | 0.07% |
2,788
-1,037
| -27% | -$49.8K |
|
383
Cogent Biosciences
COGT
$1.8B
| $134K | 0.07% |
+11,576
| New | +$134K |
|
384
Regenxbio
RGNX
$484M
| $134K | 0.07% |
5,893
+645
| +12% | +$14.6K |
|
385
Iovance Biotherapeutics
IOVA
$825M
| $133K | 0.07% |
20,782
+7,263
| +54% | +$46.4K |
|
386
Kura Oncology
KURA
$712M
| $132K | 0.07% |
10,635
+2,985
| +39% | +$37K |
|
387
Arcellx
ACLX
$3.93B
| $132K | 0.07% |
+4,245
| New | +$132K |
|
|
NGM
388
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $131K | 0.07% |
26,181
+17,854
| +214% | +$89.6K |
|
|
ITOS
389
DELISTED
iTeos Therapeutics
ITOS
| $129K | 0.07% |
6,620
+792
| +14% | +$15.5K |
|
|
BCYC
390
Bicycle Therapeutics
BCYC
$486M
| $129K | 0.07% |
4,361
-3,648
| -46% | -$108K |
|
391
Dynavax Technologies
DVAX
$1.18B
| $129K | 0.07% |
12,127
+2,157
| +22% | +$23K |
|
392
Nuvalent
NUVL
$5.82B
| $129K | 0.07% |
+4,330
| New | +$129K |
|
|
DICE
393
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $129K | 0.07% |
4,127
-3,413
| -45% | -$106K |
|
|
TVRD
394
Tvardi Therapeutics, Inc. Common Stock
TVRD
$284M
| $129K | 0.07% |
333
-39
| -10% | -$15.1K |
|
395
Xencor
XNCR
$604M
| $128K | 0.07% |
4,911
-309
| -6% | -$8.05K |
|
396
Sangamo Therapeutics
SGMO
$161M
| $127K | 0.07% |
40,600
+8,949
| +28% | +$28.1K |
|
397
Arvinas
ARVN
$565M
| $127K | 0.07% |
3,721
+821
| +28% | +$28.1K |
|
398
4D Molecular Therapeutics
FDMT
$315M
| $127K | 0.07% |
+5,731
| New | +$127K |
|
399
Seres Therapeutics
MCRB
$166M
| $127K | 0.07% |
1,131
-804
| -42% | -$90.1K |
|
400
Denali Therapeutics
DNLI
$2.21B
| $127K | 0.07% |
4,552
-323
| -7% | -$8.98K |
|